Literature DB >> 21683674

Intermediate volume on computed tomography imaging defines a fibrotic compartment that predicts glomerular filtration rate decline in autosomal dominant polycystic kidney disease patients.

Anna Caroli1, Luca Antiga, Sara Conti, Aurelio Sonzogni, Giorgio Fasolini, Patrizia Ondei, Norberto Perico, Giuseppe Remuzzi, Andrea Remuzzi.   

Abstract

Total kidney and cyst volumes have been used to quantify disease progression in autosomal dominant polycystic kidney disease (ADPKD), but a causal relationship with progression to renal failure has not been demonstrated. Advanced image processing recently allowed to quantify extracystic tissue, and to identify an additional tissue component named "intermediate," appearing hypoenhanced on contrast-enhanced computed tomography (CT). The aim of this study is to provide a histological characterization of intermediate volume, investigate its relation with renal function, and provide preliminary evidence of its role in long-term prediction of functional loss. Three ADPKD patients underwent contrast-enhanced CT scans before nephrectomy. Histological samples of intermediate volume were drawn from the excised kidneys, and stained with hematoxylin and eosin and with saturated picrosirius solution for histological analysis. Intermediate volume showed major structural changes, characterized by tubular dilation and atrophy, microcysts, inflammatory cell infiltrate, vascular sclerosis, and extended peritubular interstitial fibrosis. A significant correlation (r = -0.69, P < 0.001) between relative intermediate volume and baseline renal function was found in 21 ADPKD patients. Long-term prediction of renal functional loss was investigated in an independent cohort of 13 ADPKD patients, followed for 3 to 8 years. Intermediate volume, but not total kidney or cyst volume, significantly correlated with glomerular filtration rate decline (r = -0.79, P < 0.005). These findings suggest that intermediate volume may represent a suitable surrogate marker of ADPKD progression and a novel therapeutic target.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21683674      PMCID: PMC3157175          DOI: 10.1016/j.ajpath.2011.04.036

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  35 in total

Review 1.  Polycystic kidney disease: neoplasia in disguise.

Authors:  J J Grantham
Journal:  Am J Kidney Dis       Date:  1990-02       Impact factor: 8.860

2.  Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis.

Authors:  R A Risdon; J C Sloper; H E De Wardener
Journal:  Lancet       Date:  1968-08-17       Impact factor: 79.321

3.  Structural-functional correlations in renal disease. II. The correlations.

Authors:  L I Schainuck; G E Striker; R E Cutler; E P Benditt
Journal:  Hum Pathol       Date:  1970-12       Impact factor: 3.466

4.  The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease.

Authors:  A B Chapman; A Johnson; P A Gabow; R W Schrier
Journal:  N Engl J Med       Date:  1990-10-18       Impact factor: 91.245

5.  Everolimus in patients with autosomal dominant polycystic kidney disease.

Authors:  Gerd Walz; Klemens Budde; Marwan Mannaa; Jens Nürnberger; Christoph Wanner; Claudia Sommerer; Ulrich Kunzendorf; Bernhard Banas; Walter H Hörl; Nicholas Obermüller; Wolfgang Arns; Hermann Pavenstädt; Jens Gaedeke; Martin Büchert; Christoph May; Harald Gschaidmeier; Stefan Kramer; Kai-Uwe Eckardt
Journal:  N Engl J Med       Date:  2010-06-26       Impact factor: 91.245

6.  Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease.

Authors:  P A Gabow; A M Johnson; W D Kaehny; W J Kimberling; D C Lezotte; I T Duley; R H Jones
Journal:  Kidney Int       Date:  1992-05       Impact factor: 10.612

Review 7.  Tubulointerstitial changes as a major determinant in the progression of renal damage.

Authors:  K A Nath
Journal:  Am J Kidney Dis       Date:  1992-07       Impact factor: 8.860

8.  Volumetric measurement of renal cysts and parenchyma using MRI: phantoms and patients with polycystic kidney disease.

Authors:  K T Bae; P K Commean; J Lee
Journal:  J Comput Assist Tomogr       Date:  2000 Jul-Aug       Impact factor: 1.826

9.  Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.

Authors:  Arlene B Chapman; Lisa M Guay-Woodford; Jared J Grantham; Vicente E Torres; Kyongtae T Bae; Deborah A Baumgarten; Philip J Kenney; Bernard F King; James F Glockner; Louis H Wetzel; Marijn E Brummer; W Charles O'Neill; Michelle L Robbin; William M Bennett; Saulo Klahr; Gladys H Hirschman; Paul L Kimmel; Paul A Thompson; J Philip Miller
Journal:  Kidney Int       Date:  2003-09       Impact factor: 10.612

10.  Rate of functional deterioration in polycystic kidney disease.

Authors:  K A Franz; F C Reubi
Journal:  Kidney Int       Date:  1983-03       Impact factor: 10.612

View more
  5 in total

1.  Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Arlene B Chapman; Olivier Devuyst; Kai-Uwe Eckardt; Ron T Gansevoort; Tess Harris; Shigeo Horie; Bertram L Kasiske; Dwight Odland; York Pei; Ronald D Perrone; Yves Pirson; Robert W Schrier; Roser Torra; Vicente E Torres; Terry Watnick; David C Wheeler
Journal:  Kidney Int       Date:  2015-03-18       Impact factor: 10.612

2.  Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study.

Authors:  William E Braun; Jesse D Schold; Brian R Stephany; Rita A Spirko; Brian R Herts
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 8.237

3.  Detected renal cysts are tips of the iceberg in adults with ADPKD.

Authors:  Jared J Grantham; Sumanth Mulamalla; Connor J Grantham; Darren P Wallace; Larry T Cook; Louis H Wetzel; Timothy A Fields; K T Bae
Journal:  Clin J Am Soc Nephrol       Date:  2012-05-10       Impact factor: 8.237

4.  Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease.

Authors:  Tom J G Gevers; Melissa Chrispijn; Jack F M Wetzels; Joost P H Drenth
Journal:  BMC Nephrol       Date:  2012-04-04       Impact factor: 2.388

5.  Engineered Kidney Tubules for Modeling Patient-Specific Diseases and Drug Discovery.

Authors:  Valentina Benedetti; Valerio Brizi; Patrizia Guida; Susanna Tomasoni; Osele Ciampi; Elena Angeli; Ugo Valbusa; Ariela Benigni; Giuseppe Remuzzi; Christodoulos Xinaris
Journal:  EBioMedicine       Date:  2018-07-03       Impact factor: 8.143

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.